Director/PDMR Shareholding
Updated : 17:36
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') |
| ||||||||||||||
a) | Name | Ms E Walmsley |
| |||||||||||||
b) | Position/status | Chief Executive Officer |
| |||||||||||||
c) | Initial notification/ amendment | Initial notification |
| |||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| ||||||||||||||
a) | Name | GlaxoSmithKline plc |
| |||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 |
| |||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| ||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
| |||||||||||||
b) | Nature of the transaction | Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. |
| |||||||||||||
c) | Price(s) and volume(s) |
|
| |||||||||||||
d) | Aggregated information
Aggregated volume Price |
2340.000 £15.6560
|
| |||||||||||||
e) | Date of the transaction | 2019-04-12 |
| |||||||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) |
| |||||||||||||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||||||||||||
| a) | Name | Dr H Barron | |||||||||||||
| b) | Position/status | Chief Scientific Officer and President, R&D | |||||||||||||
| c) | Initial notification/ amendment | Initial notification | |||||||||||||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||||||
| a) | Name | GlaxoSmithKline plc | |||||||||||||
| b) | LEI | 5493000HZTVUYLO1D793 | |||||||||||||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||||||||||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| |||||||||||||
| b) | Nature of the transaction | Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan. | |||||||||||||
| c) | Price(s) and volume(s) |
| |||||||||||||
| d) | Aggregated information Aggregated volume Price |
n/a (single transaction)
| |||||||||||||
| e) | Date of the transaction | 2019-04-12 | |||||||||||||
| f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||||||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||
a) | Name | Mr R G Connor | ||||||||||
b) | Position/status | President, Global Vaccines | ||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||
b) | Nature of the transaction | Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||||||||
c) | Price(s) and volume(s) |
| ||||||||||
d) | Aggregated information
Aggregated volume Price |
701.000 £15.6560
| ||||||||||
e) | Date of the transaction | 2019-04-12 | ||||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||
a) | Name | Mr S P Dingemans | ||||||||||
b) | Position/status | Executive Director | ||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||
b) | Nature of the transaction | Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||||||||
c) | Price(s) and volume(s) |
| ||||||||||
d) | Aggregated information
Aggregated volume Price |
1766.000 £15.6560
| ||||||||||
e) | Date of the transaction | 2019-04-12 | ||||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr J Ford | ||||
b) | Position/status | SVP and General Counsel | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| ||||
b) | Nature of the transaction | Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information
Aggregated volume Price | n/a (single transaction)
| ||||
e) | Date of the transaction | 2019-04-12 | ||||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||
a) | Name | Mr N Hirons | ||||||||||
b) | Position/status | SVP, Global Ethics & Compliance | ||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||
b) | Nature of the transaction | Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||||||||
c) | Price(s) and volume(s) |
| ||||||||||
d) | Aggregated information
Aggregated volume Price |
370.000 £15.6560
| ||||||||||
e) | Date of the transaction | 2019-04-12 | ||||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr B McNamara | ||||||||
b) | Position/status | CEO, GSK Consumer Healthcare | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| ||||||||
b) | Nature of the transaction | Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
$ 40.9400 | ||||||||
e) | Date of the transaction | 2019-04-12 | ||||||||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||
a) | Name | Mr L Miels | ||||||
b) | Position/status | President, Global Pharmaceuticals | ||||||
c) | Initial notification/ amendment | Initial notification | ||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | GlaxoSmithKline plc | ||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||
b) | Nature of the transaction | Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information
Aggregated volume Price |
436.000
| ||||||
e) | Date of the transaction | 2019-04-12 | ||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||
a) | Name | Mr D Redfern | ||||||||||
b) | Position/status | Chief Strategy Officer | ||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||
b) | Nature of the transaction | Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||||||||
c) | Price(s) and volume(s) |
| ||||||||||
d) | Aggregated information
Aggregated volume Price |
626.000 £15.6560
| ||||||||||
e) | Date of the transaction | 2019-04-12 | ||||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr R Simard | ||||
b) | Position/status | President, Pharmaceuticals Supply Chain | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||
b) | Nature of the transaction | Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information
Aggregated volume Price |
n/a (single transaction)
| ||||
e) | Date of the transaction | 2019-04-12 | ||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||
a) | Name | Ms K Terrell | ||||||
b) | Position/status | Chief Digital & Technology Officer | ||||||
c) | Initial notification/ amendment | Initial notification | ||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | GlaxoSmithKline plc | ||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| ||||||
b) | Nature of the transaction | Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan. | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information
Aggregated volume Price |
146.000 $ 40.9400
| ||||||
e) | Date of the transaction | 2019-04-12 | ||||||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | ||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr P C Thomson | ||||||||
b) | Position/status | President, Global Affairs | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
359.000 £15.6560
| ||||||||
e) | Date of the transaction | 2019-04-12 | ||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.